Trastuzumab is an anti-ErbB-2 monoclonal antibody. Trastuzumab is widely used for advanced breast cancer patients with ERBB2-amplified tumors. Nevertheless, over half of these patients do not have an objective response.
References
Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. PMID: 17611206
Morrison LE, Jewell SS, Usha L, Blondin BA, Rao RD, Tabesh B, Kemper M, Batus M, Coon JS. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007 Apr;46(4):397-405. PMID: 17243161